Dr Reddy's launches generic anti-viral tablets in US market

Drug firm Dr Reddy's Laboratories has launched generic anti-viral Valganciclovir tablets in the US market.

"The company has launched Valganciclovir tablets, USP in the strength of 450 mg in the US market on December 15, 2014 and the product has been approved by the United States Food and Drug Administration (USFDA)", Dr Reddy's Laboratories said in a filing to the Bombay Stock Exchange (BSE) on Tuesday.

"The tablets are generic version of Roche's Valcyte tablets", it added.

"The Valcyte tablets brand had US sales of approximately $440 million MAT for the most recent twelve months ending in October 2014 according to IMS health", Dr Reddy's said.

Shares of Dr Reddy's Laboratories were on Tuesday trading at Rs 3,184.50 per scrip in the afternoon trade on the BSE, down 5.06 per cent from its previous close. 

"Dr Reddys Valganciclovir tablets USP 450 mg are available in bottle counts of 60", the company statement said.

According to analysts, the Hyderabad-based drug maker is set to gain with the approval as the FDA had previously cancelled the earlier tentative approval given for the drug to Ranbaxy on quality issues pertaining to its facilities.